FDA Panel Backs Galleri Multi-Cancer Early Detection Test
Author: GRAIL, Inc.
Published: 24 Sep 2026
Publication Type: Announcement
Table of Contents:
Synopsis - Definition - Overview - FAQs - Insights, Updates - Related Content
Synopsis
This report covers the favorable vote by the Molecular and Clinical Genetics Devices Panel of the U.S. Food and Drug Administration's Medical Devices Advisory Committee on GRAIL's Galleri multi-cancer early detection test, a screening tool intended for adults aged 50 and older. The 10 voting members answered three separate questions, voting unanimously that the test is safe, six to four that it is effective, and seven to two with one abstention that its benefits outweigh its risks. Galleri looks for cancer-specific methylation patterns shared by many cancer types, including cancers that currently have no recommended screening, and is meant to be used alongside guideline-recommended screenings rather than as a replacement for them. In clinical studies, the test found roughly four to seven times more cancers than standard of care alone, with most caught at earlier stages when treatment with curative intent may still be possible. The results are relevant to older adults, seniors, and people with disabilities, who may face practical barriers to arranging several separate screening appointments, since one test that can signal multiple cancers could make early detection more manageable. The FDA is not bound by the committee's advice, and a final decision is expected in the coming months.*
At a Glance
- 1 - The FDA designated Galleri a Breakthrough Device in 2018, and GRAIL filed its PMA application on January 29, 2026.
- 2 - When a cancer signal is found, the test predicts where in the body the cancer likely originated, helping clinicians guide diagnostic follow-up.
- 3 - More than 200 physicians, nurses, professional societies, patients, and advocates submitted support through the public docket and open comment period.
- 4 - Galleri's evidence base includes FDA-approved Investigational Device Exemption studies such as PATHFINDER 2 in North America and the NHS-Galleri trial in England.
Topic Definition
- Multi-Cancer Early Detection Test
A multi-cancer early detection test, often shortened to MCED, is a screening test designed to look for signs of many different cancers at the same time, usually before a person has any symptoms. Rather than examining one organ, as a mammogram or colonoscopy does, these tests analyze fragments of genetic material in the body for patterns linked to cancer, such as changes in DNA methylation. If a cancer signal is found, some tests can also estimate which part of the body the cancer likely came from, helping doctors decide on the next diagnostic steps. MCED tests are intended to add to, not replace, established screening programs, and a positive result must be confirmed through further medical evaluation.
Overview
FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the Committee) of the U.S. Food and Drug Administration (FDA) for the approval of the Premarket Approval (PMA) application of the Galleri® multi-cancer early detection test (MCED).
In three separate votes, the 10 voting members of the Committee considered Galleri's safety, effectiveness and overall benefit-risk profile for screening for the early detection of multiple types of cancer in adults aged 50 years and older. The Committee voted seven to two with one abstention that the benefits of Galleri outweigh its risks, unanimously in support of Galleri's safety, and six to four in support of Galleri's effectiveness.
"The Galleri test was developed to improve the effectiveness and efficiency of our national cancer screening program by adding multi-cancer early detection to recommended screening-helping find more cancers safely, when they may be easier and less costly to treat, and it still may be possible for a patient to receive treatment with curative intent," said Josh Ofman, MD, MSHS, CEO at GRAIL. "Today's vote reinforces the strength of Galleri's clinical evidence. We believe the panel's recommendations reaffirm a high evidence bar that GRAIL has set for a multi-cancer early detection test. GRAIL is committed to working with the FDA as it completes its review of Galleri, the first PMA submission for a multi-cancer early detection test."
The Galleri test is designed to detect cancer-specific methylation patterns shared by many types of cancer before symptoms appear, including cancers that do not have recommended screening today. When a cancer signal is detected, Galleri is designed to predict the cancer signal origin with high accuracy to help guide diagnostic evaluation. The test is intended to be used in addition to, and not as a replacement for, guideline-recommended screenings.
"We are heartened by the more than 200 physicians, nurses, professional societies, patients, patient advocates, and others who shared their support for Galleri through the written public docket and open comment period during the panel," said Ofman. "Their voices reflect the real-world urgency of finding more cancers, when outcomes can be improved."
Galleri is the only MCED test supported by large interventional and randomized controlled studies in intended-use populations, including FDA-approved Investigational Device Exemption studies (IDEs), namely PATHFINDER 2 in North America and the landmark NHS-Galleri trial in England. GRAIL's clinical development program is one of the largest in cancer screening with participants across multiple large-scale prospective studies. In clinical studies, Galleri has detected approximately four to seven times more cancers compared to standard of care alone, with most Galleri-detected cancers found at earlier stages, when treatment with curative intent may be possible, while maintaining a low false-positive rate and high Cancer Signal Origin prediction accuracy.
The FDA designated Galleri as a Breakthrough Device in 2018. GRAIL submitted its PMA application for Galleri to the FDA on Jan. 29, 2026.
The FDA convenes advisory committees to obtain independent expert advice. The agency is not bound by the Committee's recommendations, though it takes them into consideration when making final regulatory decisions. The FDA is expected to make a final decision on the Galleri PMA in the coming months.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology. GRAIL is headquartered in Sunnyvale, Calif. with locations in Washington, D.C., North Carolina, and the United Kingdom.
Frequently Asked Questions
NOTE: Researched FAQs by Disabled World (DW)
How is the Galleri test performed?
Galleri is performed using a standard blood draw, which is then sent to a laboratory for analysis. No imaging, fasting, or bowel preparation is required, which can make it easier for many people to complete.
Can people currently get the Galleri test in the United States?
Galleri has been available in the United States by prescription as a laboratory-developed test while the FDA reviews its premarket approval application. Approval would mark the first formal FDA authorization of a multi-cancer early detection test.
Does insurance or Medicare cover multi-cancer early detection tests?
Coverage is limited, and many people currently pay out of pocket for these tests. Legislation has been proposed in Congress to allow Medicare coverage of multi-cancer early detection tests once they receive FDA approval.
What happens if a Galleri test detects a cancer signal?
A positive result is not a diagnosis. A physician will typically order follow-up tests such as imaging or biopsies, guided by the predicted cancer signal origin, to confirm whether cancer is present.
Does a negative Galleri result mean a person does not have cancer?
No. A negative result means no cancer signal was detected, but the test does not find every cancer. People should continue with all recommended routine screenings and report any symptoms to their doctor.
What is DNA methylation and why does it matter for cancer detection?
DNA methylation is a chemical process that helps control which genes are switched on or off. Cancer cells often show abnormal methylation patterns, and these patterns can be picked up in DNA fragments that tumors release into the bloodstream.
What does it mean when an FDA advisory committee votes in favor of a device?
An advisory committee gives the FDA independent expert advice on safety, effectiveness, and benefits versus risks. The FDA considers this advice but makes the final decision on its own and is not required to follow the vote.
Why could multi-cancer screening be helpful for people with disabilities?
Some people with disabilities face challenges with transportation, physical access to equipment, or tolerating certain procedures. A single blood test that screens for many cancers could reduce the number of appointments and procedures needed for early detection.
Insights, Analysis, and Developments
Editorial Note: The advisory vote marks a notable moment for cancer screening in the United States, since Galleri is the first multi-cancer early detection test to be submitted for FDA premarket approval. The narrower margin on effectiveness shows that experts are still weighing how well the test performs in everyday screening, even while confidence in its safety is strong. For adults over 50, and particularly for seniors and people with disabilities who may find repeated imaging or invasive procedures hard to arrange or tolerate, a test that can point toward several cancers at once could make regular screening more realistic. Readers should keep in mind that a panel recommendation is not the same as approval, and that any positive result still needs follow-up diagnostic testing with a physician before a cancer can be confirmed.*
Attribution/Source(s): This quality-reviewed publication was selected for publishing by the editors of Disabled World (DW) due to its relevance to the disability community. Originally authored by GRAIL, Inc. and published on 24 Sep 2026, this content may have been edited for style, clarity, or brevity.
* Editorial additions by Ian C. Langtree.